10-Q: RxSight Q3 2025: LDD Sales Decline, Losses Mount

RxSight, Inc. reports a 14.1% revenue decrease in Q3 2025 driven by a significant drop in LDD sales, despite continued growth in Light-Adjustable Lens (LAL) implants, leading to increased operating losses and ongoing litigation.

Summary

• Net loss for Q3 2025 was $9.8 million, a 54.9% increase compared to $6.3 million for Q3 2024.
• Net loss for the nine months ended September 30, 2025, was $29.8 million, a 38.5% increase compared to $21.5 million for the same period in 2024.
• Total sales decreased by 14.1% to $30.3 million in Q3 2025 from $35.3 million in Q3 2024.
• The sales decrease was primarily due to a 68% reduction in Light Delivery Device (LDD) units sold, from 78 units in Q3 2024 to 25 units in Q3 2025.
• Light-Adjustable Lens (LAL) sales increased by 6% in Q3 2025 compared to Q3 2024, with 26,045 LALs sold.
• Gross profit decreased by 3.9% to $24.2 million in Q3 2025 from $25.2 million in Q3 2024.
• Gross margin improved to 79.9% in Q3 2025 from 71.4% in Q3 2024, driven by a favorable product mix with a higher percentage of LAL revenue.
• Operating expenses increased by 5.7% to $36.4 million in Q3 2025 from $34.4 million in Q3 2024.
• Selling, general and administrative (SG&A) expenses increased by $1.7 million (6.8%) in Q3 2025, primarily due to increased selling and marketing costs and stock-based compensation.
• Research and development (R&D) expenses increased by $0.2 million (2.5%) in Q3 2025, mainly due to increased overhead and stock-based compensation.
• Cash, cash equivalents, and short-term investments were $227.5 million as of September 30, 2025, down from $237.2 million at December 31, 2024.
• The company has an accumulated deficit of $651.9 million as of September 30, 2025.
• Two securities class action lawsuits and two shareholder derivative actions have been filed against the company and certain officers/directors, alleging false/misleading statements regarding product demand and financial guidance, and lack of internal controls.

Sentiment

Score: 3

Explanation: The significant decline in LDD sales and increased net losses are concerning, indicating a slowdown in market adoption for the core system. While LAL sales show growth and gross margin improved due to product mix, the overall financial performance for the quarter and year-to-date is negative. The ongoing legal proceedings add further uncertainty and potential costs. Management's forward-looking statements about not needing to raise capital to reach profitability are optimistic given the current losses, but they also acknowledge the possibility of opportunistic capital raises.

Positives

• Light-Adjustable Lens (LAL) sales increased by 6% in Q3 2025 compared to Q3 2024, indicating continued adoption of the core product.
• Gross margin improved significantly to 79.9% in Q3 2025 from 71.4% in Q3 2024, driven by a favorable product mix with a higher percentage of LAL revenue.
• Existing cash, cash equivalents, and short-term investments of $227.5 million are believed to be sufficient to fund operations for at least the next 12 months.
• Management does not anticipate the need to raise additional capital or incur additional debt to reach profitability from operations, though they may opportunistically seek capital under advantageous circumstances.
• A full realignment of the U.S. commercial organization into a unified Customer Success Organization was completed to better support existing customers and position for future growth.
• Research and development activities are focused on enhancements to the RxSight system, expanding indications for use, and reducing manufacturing costs.

Negatives

• Total sales decreased by 14.1% in Q3 2025 compared to Q3 2024, primarily due to a 68% reduction in Light Delivery Device (LDD) unit sales.
• Net loss increased by 54.9% in Q3 2025 and 38.5% for the nine months ended September 30, 2025, compared to the prior year periods.
• Loss from operations increased by 32.0% in Q3 2025 and 30.6% for the nine months ended September 30, 2025.
• The company has a history of recurring net losses and negative cash flows from operating activities since inception, with an accumulated deficit of $651.9 million.
• LDD sales declined sequentially in Q2 and Q3 2025, which management believes contributed to reduced demand for LDDs by prospective customers.
• Interest and other income decreased by 18.2% in Q3 2025 due to reduced interest income from lower cash balances and lower interest rates.
• The company is involved in multiple securities class action and shareholder derivative lawsuits alleging false/misleading statements and lack of internal controls.

Risks

• Failure to effectively train the sales force, increase sales and marketing capabilities, or develop broad brand awareness could impede growth.
• Continued net operating losses are expected, and profitability, if achieved, may not be sustainable.
• The need to raise additional capital may arise, and it might not be available on acceptable terms or at all, leading to dilution or restrictive debt covenants.
• Success depends heavily on the RxSight system; failure to successfully market and sell it would significantly harm business prospects.
• Significant competition from larger, well-capitalized companies in the medical device industry.
• Difficulties in obtaining regulatory clearance/approval or successfully marketing products internationally.
• Global economic, political, and market conditions, including U.S. credit rating downgrades and inflation, may adversely affect business.
• Potential for significant disruption in information technology systems or breaches of data security.
• Inability to obtain, maintain, protect, and enforce patent and other intellectual property protection.
• Failure to protect the confidentiality of trade secrets and other proprietary information.
• Inability to protect intellectual property rights throughout the world.
• Failure to obtain and maintain necessary regulatory clearances or approvals for products, or delays in approvals for future products/indications.
• Dependence on third parties, including single and sole source suppliers, for components and subcomponents, making the company vulnerable to supply disruptions and price fluctuations.
• Volatility in the stock price, with potential for investors to lose all or part of their investment.
• Difficulty in maintaining an active, liquid, and orderly trading market for common stock.
• Sales of a substantial number of shares could cause the stock price to fall.
• Failure to recruit, retain, manage, and motivate qualified executives and the management team.
• Current and future litigation proceedings, including the pending securities class action, could adversely affect the business.
• Adoption of products depends on appropriate doctor training; inadequate training may lead to negative patient outcomes and affect adoption.
• Commercial success depends on significant market acceptance among patients and doctors, which may be slow due to various factors (up-front LDD investment, patient confusion, UV protective glasses requirement, additional clinic visits).
• The RxSight system involves surgical risks and is contraindicated in certain patients, limiting adoption.
• Facilities becoming damaged or inoperable, or being required to vacate a facility, could disrupt manufacturing and increase costs.
• Technological change may adversely affect sales and cause products to become obsolete.
• Results of earlier clinical studies may not be predictive of future results, and planned studies may not establish adequate safety/efficacy.
• Unauthorized third parties may access devices or related products/services and modify them inconsistently with FDA clearances, creating user risks.
• Expenditure of limited resources on a particular product/indication may cause failure to capitalize on more profitable opportunities.
• Inability to develop, license, or acquire new products or enhance existing ones to keep pace with technology and customer requirements.
• Coverage and adequate reimbursement, or patient ability to pay, may not be available, diminishing sales.
• Product liability lawsuits could incur substantial liabilities and require limiting/halting marketing/sale of products.
• Compliance with the EU Medical Device Regulation, UK regulations, and other foreign regulations may be costly and disruptive.
• Inadequate funding for the FDA and other government agencies could hinder their ability to perform normal business functions.
• Global operations expose the company to numerous and conflicting legal/regulatory requirements, including anti-bribery and anti-corruption laws.
• Failure of third parties (consultants, suppliers) to meet contractual/regulatory obligations could adversely affect the business.
• Failure to maintain proper and effective internal controls could impair the ability to produce accurate financial statements.
• Provisions in corporate documents and Delaware law might discourage, delay, or prevent a change in control.
• Bylaws specify exclusive forums for disputes, potentially limiting stockholder ability to choose favorable judicial forums.
• Taxing authorities may assert that sales and use, VAT, or similar taxes should have been collected, leading to liabilities.
• Changes in tax laws or regulations could adversely affect the business.
• Business disruptions (natural disasters, power shortages, etc.) could harm revenue and financial condition.
• Inability to accurately forecast customer demand for products and manage inventory could materially harm results.

Future Outlook

The company expects revenue to increase in absolute dollars as it expands its sales organization and territories, adds customers, expands the base of trained doctors, and increases product awareness, leading to more procedures. It anticipates continued net operating losses into the foreseeable future due to ongoing research and development, and sales and marketing activities. The company believes its adjustable lens solution can address a broad range of cataract surgery patients and aims to gain market share in the premium IOL market. It plans to invest in business growth, including new geographic markets and product enhancements, and does not anticipate needing to raise additional capital to reach profitability from operations, though it may opportunistically seek capital under advantageous circumstances.

Management Comments

• "We expect to continue to incur net operating losses into the foreseeable future."
• "We believe that existing cash resources will be sufficient to meet projected operating requirements for at least 12 months from the date of issuance of the accompanying condensed consolidated financial statements."
• "Although, based on our current planned operations, we do not anticipate the need to raise additional capital or incur additional debt in order to reach profit from operations... we may opportunistically seek to raise capital under advantageous circumstances from time to time."
• "Following several years of rapid growth, sales moderated in 2025, and we expect our commercial realignment initiatives to position the company for renewed revenue growth."
• "We plan to drive continued expansion by supporting existing practices and strategically expanding our LDD installed base and helping new adopters in achieving early success and sustained long-term growth."
• "We believe our adjustable lens solution can be used to address a broad range of cataract surgery patients, including those that would otherwise elect for a conventional cataract procedure today."
• "We believe our RxSight system offers doctors and patients a significantly more reliable approach that can consistently deliver optimal, fully customized visual outcomes with few compromises, ultimately driving broad adoption and establishing it as the standard of care for premium cataract procedures."
• "We believe that there is an opportunity to gain market share in the premium intraocular lens (IOL) market segment and also increase the penetration of premium IOLs in the broader market by converting doctors and patients currently electing for conventional cataract surgery."
• "We believe that current non-adjustable premium IOL offerings often cannot deliver on patient expectations regarding their desire to see at near, intermediate and far distances without reliance on glasses and to avoid troubling side effects such as glare, halos and loss of contrast sensitivity."
• "We believe we have meritorious defenses, vehemently deny the allegations, and intend to defend the case vigorously" regarding the legal proceedings.

Industry Context

The company operates in the intensely competitive medical device industry, specifically the intraocular lens (IOL) market, which is characterized by rapid technological change. It competes with major players like Alcon, Johnson & Johnson, and Bausch + Lomb, all of whom are actively developing new IOL products. The premium cataract surgery market is noted as underpenetrated due to doctor reluctance and patient confusion, which RxSight aims to address with its unique adjustable lens technology. The industry is also subject to increasing scrutiny over pricing and cost-effectiveness from government and private payors, alongside ongoing global economic uncertainties and supply chain constraints.

Comparison to Industry Standards

• NA

Legal Proceedings

• **Securities Class Actions:** On July 22, 2025, Makaveev v. RxSight, Inc., et al. (No. 8:25-cv-01596) was filed in the U.S. District Court for the Central District of California against the company and certain officers. It alleges claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and SEC Rule 10b-5, for materially false and misleading statements and omitted material adverse facts regarding product demand and financial guidance.
• On September 16, 2025, Gmesi v. RxSight, Inc., et al. (No. 25-cv-02093) was filed, a related putative securities class action. On October 6, 2025, the court consolidated Makaveev and Gmesi actions, appointed a lead plaintiff, and approved lead counsel, re-captioning as In re RxSight Securities Litigation (No. 8:25-cv-01596-FWS-KES). Plaintiffs seek unspecified compensatory and punitive damages, and reasonable costs and expenses, including attorneys fees.
• **Shareholder Derivative Actions:** On August 18, 2025, Swift v. Kurtz, et al. (Case No. 8:25-cv-01820-FWS-KES) was filed in the U.S. District Court for the Central District of California against certain officers and directors, with the company as a nominal defendant. It alleges false and misleading statements and omitted material adverse facts regarding declining sales, product demand, financial guidance, and lack of internal controls. Claims alleged violations of Section 14(a) of the Exchange Act, breaches of fiduciary duties, aiding and abetting, unjust enrichment, and waste of corporate assets.
• On October 2, 2025, the court ordered staying proceedings in the Swift action until final resolution of the Securities Class Actions. On October 10, 2025, Yost v. Kurtz, et al. (Case No. 8:25-cv-2295) was filed, a related shareholder derivative action. It asserts claims for alleged breaches of fiduciary duties, gross mismanagement, waste of corporate assets, unjust enrichment, aiding and abetting, insider trading, and alleged violations of Section 14(a) of the Exchange Act. Plaintiffs seek unspecified damages on behalf of the company, declaratory relief, constructive trust, punitive damages, corporate governance reforms, and costs/attorneys fees.
• The company believes it has meritorious defenses, vehemently denies the allegations, and intends to defend the cases vigorously. An unfavorable resolution could materially adversely affect the business, results of operations, and financial condition.

Stakeholder Impact

• **Shareholders:** Potential for dilution if future capital raises involve equity. Stock price volatility is a risk. Ongoing litigation could lead to substantial costs, diverting resources and potentially impacting share value. Shareholder derivative actions seek damages on behalf of the company and corporate governance reforms.
• **Employees:** Increased costs for employee-related expenses are expected as a public company. The company's success is highly dependent on attracting and retaining skilled executive officers and employees, facing intense competition for talent.
• **Customers (Ophthalmic Practices, ASCs):** Slower adoption of RxSight technology by practices and doctors has led to reduced LDD sales. Customers must make a significant up-front investment in the LDD. Adoption depends on appropriate training and perceived benefits over alternatives. Potential for negative patient outcomes due to inadequate training or off-label use could impact customer confidence.
• **Suppliers:** Reliance on third parties, including single and sole source suppliers, makes the company vulnerable to supply disruptions and price fluctuations, particularly with global lead times and inflation. Suppliers passing on higher prices could increase costs.
• **Creditors:** Ongoing net losses and negative cash flows from operations could impact the company's ability to meet future funding needs, though current cash resources are deemed sufficient for 12 months. Debt financing, if pursued, may impose restrictive covenants.

Next Steps

• Continue to expand the sales organization and sales territories.
• Add new customers and expand the base of doctors trained to use products.
• Expand awareness of products with new and existing customers.
• Doctors to perform more procedures using products.
• Selectively pursue commercial expansion in international markets, prioritizing high-potential opportunities.
• Seek new regulatory approvals in large foreign cataract markets with complex regulatory processes (e.g., Asia and Europe).
• Make significant investments in sales, marketing, clinical, and practice development organizations.
• Grow the business by increasing LAL adoption and expanding the LDD installed base.
• Focus research and development on products, software upgrades, and programs to improve clinical outcomes, customer experience, expand indications for use, reduce manufacturing costs, and support lifecycle management.
• Conduct additional development and clinical studies to provide clinical evidence of safety and effectiveness for existing and future products.
• May seek to acquire or invest in additional businesses, products, or technologies.
• Expand marketing efforts through print, digital, social media, education, and other customer tools.
• Continue to incur increased costs as a public company for employee-related expenses, D&O insurance, audit fees, SOX compliance, legal fees, and investor relations.
• Defend vigorously against the pending securities class action and shareholder derivative lawsuits.
• FDA will begin to enforce the QMSR requirements upon the effective date, February 2, 2026.
• EU MDR transition timelines: December 2027 for higher-risk Class III and implantable IIb devices; December 2028 for lower-risk Class I and IIa devices.
• European Commission's adequacy decision regarding UK's data protection framework must be renewed in 2025.

Key Dates

Recommendation

The filing reveals a concerning decline in LDD sales, a key driver for future LAL adoption, leading to a substantial increase in net losses and negative cash flow from operations. While LAL sales show some growth and gross margin improved due to product mix, the overall trend indicates a significant slowdown in market penetration for the core system. The company faces intense competition and numerous operational risks, including supply chain vulnerabilities and the need for significant ongoing R&D and marketing investments. Furthermore, the multiple securities class action and shareholder derivative lawsuits introduce considerable legal and reputational risk, with potential for substantial costs and management distraction. Given the deteriorating financial performance, significant operational challenges, and escalating legal uncertainties, a seasoned investor would likely view this filing as a strong indicator to sell or avoid the stock until clear signs of operational turnaround and resolution of legal issues emerge.

Keywords

RxSight, Light Adjustable Lens, LAL, LDD, Cataract Surgery, Intraocular Lens, IOL, Medical Device, Ophthalmology, Financial Results, SEC Filing, 10-Q, Earnings, Revenue, Net Loss, Stock, Investment, Healthcare, Regulation, Litigation, Product Development, Market Share, Commercialization, Supply Chain, Intellectual Property, Corporate Governance